Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support cancer research at Fred Hutch.

NOTE: Last year’s event sold out in advance, and space is limited. Buy your tickets early to save your seat.

PROGRAM

1 p.m. | Registration

1:30 p.m. | Welcome Remarks 

• Kelly O’Brien, vice president of philanthropy, Fred Hutch*
• Luke Timmerman

1:35 p.m. | Opening keynote

• Harmit Malik, investigator, Howard Hughes Medical Institute; and full member, division of basic sciences, Fred Hutchinson Cancer Research Center, Seattle 

2:05 p.m. | New Ideas for Cancer (10 minutes each)

• Clayton Knox, chief operating officer, Mavupharma
• Carla Grandori, CEO, SEngine Precision Medicine
• Sam Blackman, founder and chief medical officer, Day One Therapeutics
• Heidi Hagen, co-founder and chief strategy officer, Vineti*
• Jonathan Drachman, CEO, Neoleukin Therapeutics
• Julie Eastland, CFO and chief business officer, Rainier Therapeutics

3:05 p.m. | Cancer Investment. What are the Big Stories Hardly Anyone’s Talking About?

• Steve Harr, co-founder and CEO, Sana Biotechnology (moderator)
• Peter Thompson, private equity partner, OrbiMed; co-founder, Silverback Therapeutics
• Tom Daniel, venture partner, ARCH Venture Partners
• Mitchell Gold, executive chairman and CEO, Alpine Immune Sciences

3:25 p.m. | Venture Financing Models. When to Go Big? When is Small Beautiful?

• Bob More, partner, Alta Partners (moderator)
• Racquel Bracken, vice president, Venrock
• Thong Le, CEO, Accelerator Life Science Partners
• Charlotte Hubbert, partner, Gates Foundation Venture Capital

3:45 p.m. | BREAK

4:10 p.m. | New Information, New Insights for Cancer & Beyond

• Iva Toudjarska, SVP, BRIDGEs Partnerships North America and NewCos, Evotec (moderator)
• Chad Robins, co-founder and CEO, Adaptive Biotechnologies
• Brad Gray, CEO, NanoString Technologies

4:40 p.m. | The Costs for Patients

• Veena Shankaran, co-director, Hutchinson Institute for Cancer Outcomes Research
• Robin Yabroff, strategic director, economic burden of cancer, American Cancer Society

5:10 p.m. | Closing Conversation. The Future of Data Science in Cancer

• Gary Gilliland, president and director, Fred Hutch
• Matt McIlwain, chair, board of trustees, Fred Hutch
• Natasha Hernday, SVP of corporate development, Seattle Genetics (moderator)

5:40 p.m. | A Word on the Kilimanjaro Climb to Fight Cancer

• Luke Timmerman

5:45 p.m. | NETWORKING

6:00 p.m. | END

Sponsors:

• Veracyte
• Nektar Therapeutics
• Alexandria Real Estate Equities 
• Exact Sciences
• ATUM Bio
• Foundation Medicine
• Madryn Asset Management
• RiverVest Venture Partners
• Servier
• Sofinnova
• Takeda Pharmaceuticals
• 5AM Ventures
• Antibody Solutions
• Blueprint Medicines
• JP Morgan
• Mirati Therapeutics, Inc
• Moore & Van Allen, PLLC
• Pfizer
• Toft Group
• Zymeworks

*Denotes Kilimanjaro climber